Antibody drug conjugates (ADCs) link cytotoxic drugs to tumor-targeting antibodies such as trastuzumab deruxtecan (HER2-positive or HER2-low) [40]and sacituzumab govitecan (TNBC) [41] improved objective response rates (ORR) and progression-free survival (PFS) compared to chemotherapy. Here, ERBB2 is linked to neoplasm.